Jacobi Capital Management LLC Has $1.10 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Jacobi Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,139 shares of the biopharmaceutical company’s stock after acquiring an additional 20 shares during the period. Jacobi Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,096,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its position in Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the period. Capital World Investors increased its position in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after acquiring an additional 23,146 shares during the period. Putnam Investments LLC increased its position in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the period. Norges Bank bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $932,571,000. Finally, Charles Schwab Investment Management Inc. increased its position in Regeneron Pharmaceuticals by 3.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock worth $545,081,000 after acquiring an additional 22,558 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on REGN shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. JPMorgan Chase & Co. raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,067.23.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $6.14 during mid-day trading on Monday, reaching $1,069.74. The company had a trading volume of 299,549 shares, compared to its average volume of 469,325. The company’s 50 day simple moving average is $1,025.07 and its 200 day simple moving average is $972.23. Regeneron Pharmaceuticals, Inc. has a 1-year low of $721.51 and a 1-year high of $1,106.16. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The company has a market capitalization of $117.87 billion, a price-to-earnings ratio of 31.50, a P/E/G ratio of 2.20 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

Insider Buying and Selling

In related news, EVP Joseph J. Larosa sold 1,866 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares in the company, valued at approximately $41,311,496.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Joseph J. Larosa sold 1,866 shares of the firm’s stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total transaction of $2,031,980.70. Following the transaction, the executive vice president now owns 37,937 shares of the company’s stock, valued at approximately $41,311,496.15. The disclosure for this sale can be found here. Insiders have sold a total of 65,074 shares of company stock worth $64,546,123 in the last ninety days. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.